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Giardia lamblia is an anaerobic aerotolerant eukaryotic parasite of the
intestines. It is believed to have diverged early from eukarya during evolution
and is thus lacking in many of the typical eukaryotic organelles and biochemical
pathways. Most conspicuously, mitochondria and the associated machinery of
oxidative phosphorylation are absent; instead, energy is derived from substrate-
level phosphorylation. Here, the 1.75 A ˚ resolution crystal structure of G. lamblia
aldose reductase heterologously expressed in Escherichia coli is reported. As
in other oxidoreductases, G. lamblia aldose reductase adopts a TIM-barrel
conformation with the NADP
+-binding site located within the eight  -strands of
the interior.
1. Introduction
1.1. Giardia lamblia
G. lamblia is the etiological agent of giardiasis, a common cause
of diarrheal disease in the developing world. It is an anaerobic
aerotolerant eukaryotic parasite of the lower intestine. Giardia sp.
are believed to be basal eukaryotes, with a minimized genome and
simpliﬁed metabolic pathways (Morrison et al., 2007). Mitochondria
and the machinery of oxidative phosphorylation are absent, with
energy being derived from substrate-level phosphorylation. Carbo-
hydrate metabolism is largely limited to d-glucose (Lindmark, 1980),
while other sugars, sugar alcohols, Krebs-cycle intermediates and
organic acids have not been found to be utilized. Glucose is oxidized
to ethanol and acetate as the fermentation end products (Lindmark,
1980; Jarroll et al., 1981; Schoﬁeld et al., 1991), with ethanol being the
dominant product under anaerobic conditions and acetate predomi-
nating under aerobic conditions. When cultured in glucose-depleted
media, Giardia grow slowly, achieve lower cell densities and secrete
little ethanol (Schoﬁeld et al., 1990). While glucose appears to be
the preferred carbon source, it is not however essential for Giardia
growth. In the absence of glucose the carbon skeletons of amino acids
are used as a substitute, with alanine secreted as the waste product.
Ethanol production is largely absent under glucose-limited condi-
tions. Alcohol dehydrogenase (ADH), while present in Giardia, does
not appear to play a role in the production of the ethanol waste
product. Cultures grown in the presence of pyrazole, an inhibitor
of ADH, show no reduction in ethanol production. Instead, it is
believed that ethanol is produced by the reduction ofacetaldehyde by
aldose reductase in an NADPH-dependent reaction. Giardia grown
in the presence of sodium valproate, an inhibitor of aldose reductase,
show diminished ethanol production and limited growth (Schoﬁeld et
al., 1991).
1.2. Aldose reductase
Aldose reductases (EC 1.1.1.21) are ubiquitous NADPH-depen-
dent oxidoreductases that catalyze the reduction of aldehydes to
alcohols. As the name suggests, the aldehyde substrates have been
classically characterized as aldose sugars; however, in recent years
there has been an increased appreciation of the potential of theseenzymes to detoxify small aldehydes. Typical aldose reductases
exhibit the TIM-barrel fold with eight  -helices on the exterior and
an eight-stranded  -barrel in the interior. Binding of the NADPH
cofactor is facilitated by a deep elliptical pocket near the C-terminal
end of the  -barrel (Borhani et al., 1992; Wilson et al., 1992; Rondeau
et al., 1992). Mutagenic studies have shown that tight cofactor binding
is dependent on a conserved arginine residue (Arg269 in PDB entry
3kbr; Bohren et al., 2005). The active site consists of two distinct
pockets: a rigid anion-binding pocket and a ﬂexible hydrophobic
speciﬁcity pocket. Athird region near the C-terminus has been shown
to change position upon binding certain ligands (Urzhumtsev et al.,
1997; Kinoshita et al., 2002; Podjarny et al., 2004). Aldose reductase is
common to both prokaryotes and eukaryotes, with TIM-barrel folds
being reported from a diversity of species. Aldose reductase functions
by a sequential ordered mechanism (Kubiseski et al., 1992; Grimshaw
et al., 1995), with NADPH being bound before substrate. Activity
involves a stereospeciﬁc transfer of the 4-pro-R hydride from
NADPH to the substrate carbonyl C atom followed by the proton-
ation of the substrate carbonyl O atom by a conserved tyrosine
residue (Tyr40 in 3kbr). Proton transfer in the active site is assisted by
a hydrogen bond between the active tyrosine and the "-amino group
of a conserved lysine (Lys71 in 3kbr), which is itself linked by a salt
bridge to a conserved aspartic acid (Asp35 in 3kbr). The substrate is
oriented in the active site by a conserved histidine residue (His104 in
3kbr) (Del Corso et al., 2008).
Owing to its role in human disease, human aldose reductase has
been the subject of over thirty years of intense research. In diabetic
hyperglycemia, the hexokinase of insulin-independent tissues
becomes saturated with glucose, causing excess glucose to instead be
shuntedintothepolyolpathway,wherealdosereductaseconvertsitto
sorbitol. Disease results from sorbitol-induced hyperosmotic swelling
and oxidative stress owing to the lowered glutathione concentration
caused by the depletion of cellular NADPH reserves. A large number
of inhibitors have been identiﬁed that bind the active site and many
crystal structures of mammalian aldose reductases with bound inhi-
bitors have been solved. Unfortunately, despite these efforts, very few
of these compounds have made it past clinical trials (Del Corso et al.,
2008).
2. Methods
2.1. Protein expression and purification
Full-length aldose reductase (Morrison etal.,2007)from G.lamblia
ATCC 50803 was cloned into pAVA0421 vector (Alexandrov et al.,
2004) by ligand-independent cloning (LIC; Aslanidis & de Jong,
1990) to produce a construct with an N-terminal hexahistidine tag
that is cleavable with 3C protease (the entire tag sequence was
MAHHHHHHMGTLEAQTQ0GPGS-ORF, in which the 3C clea-
vage site is marked by a prime). Protein was expressed in Escherichia
coli BL21 (DE3) cells in 2 l auto-induction medium (Studier, 2005) in
a LEX bioreactor (Harbinger, Markham, Ontario, Canada) at 293 K
for 72 h, after which the harvested cells were ﬂash-frozen in liquid
nitrogen. The frozen cell pellet was thawed and resuspended by
vortexing in 200 ml lysis buffer [20 mM HEPES pH 7.4, 300 mM
NaCl, 5% glycerol, 30 mM imidazole, 0.5% CHAPS, 10 mM MgCl2,
3m M  -mercaptoethanol, 1.3 mg ml
 1 protease-inhibitor cocktail
(Roche, Basel, Switzerland) and 0.05 mg ml
 1 lysozyme]. The cell
suspension was packed on ice and disrupted by sonication for 15 min
in 5 s pulses at 70% amplitude using a Branson 450D Soniﬁer
(Branson Ultrasonics, Danbury, Connecticut, USA). The lysate was
incubated with 20 ml Benzonase nuclease (EMD Chemicals,
Gibbstown, New Jersey, USA) for 40 min at room temperature under
gentle agitation. The lysate was clariﬁed by centrifugation with a
Sorvall RC5 at 10 000 rev min
 1 for 60 min at 277 K in a F14S rotor
(Thermo Fisher, Waltham, Massachusetts, USA). The clariﬁed solu-
tion was syringe-ﬁltered through a 0.45 mm cellulose acetate ﬁlter
(Corning Life Sciences, Lowell, Massachusetts, USA). The tagged
protein was puriﬁed by afﬁnity chromatography using a HisTrap FF
5 ml column (GE Biosciences, Piscataway, New Jersey, USA) equi-
librated in binding buffer (25 mM HEPES pH 7.0, 300 mM NaCl,
5% glycerol, 30 mM imidazole, 1 mM DTT) and eluted with 500 mM
imidazole in the same buffer. To cleave the N-terminal afﬁnity tag,
peak fractions were pooled and assayed for concentration by 280 nm
spectrophotometry; 3C protease (Alexandrov et al., 2001) was mixed
with the target in a 1:50 ratio and dialyzed overnight at 277 K against
cleavage buffer (20 mM HEPES pH 7.6, 200 mM NaCl, 5% glycerol,
1m M DTT). Uncleaved target, protease and cleaved tag were
removed by a second round of afﬁnity chromatography using a 5 ml
HisTrap column. The ﬂowthrough and wash from secondary afﬁnity
chromatography were pooled and concentrated using an Amicon
Ultra-15 30 kDa molecular-weight cutoff concentrator (Millipore,
Billerica, Massachusetts, USA). The concentrated sample was further
puriﬁed by size-exclusion chromatography (SEC) using a Superdex
75 26/60 column (GE Biosciences) equilibrated in SEC buffer
(20 mM HEPES pH 7.0, 300 mM NaCl, 5% glycerol and 2 mM DTT)
attached to an A ¨ KTAprime plus FPLC system (GE Biosciences).
Peak fractions were collected and assessed for purity by SDS–PAGE
on 4–12% NuPAGE gels (Invitrogen, Carlsbad, California, USA)
with Coomassie staining using SimplyBlue Safestain (Invitrogen).
Pure fractions were pooled, concentrated to 23 mg ml
 1 and ﬂash-
frozen in liquid nitrogen. The ﬁnal concentration was determined by
280 nm spectrophotometry and the ﬁnal purity was assayed by SDS–
PAGE.
2.2. Crystallization
With the puriﬁed protein at a concentration of 25.2 mg ml
 1 in
SEC buffer, two sparse-matrix screens were set up using JCSG+
(Emerald BioSystems, Bainbridge Island, Washington, USA), PACT
(Molecular Dimensions, Suffolk, England), Index and Crystal Screen
(Hampton Research, Aliso Viejo, California, USA) following an
extended Newman’s strategy (Newman et al., 2005). 0.4 ml protein
solution was mixed with 0.4 ml well solution and equilibrated against
100 ml reservoir using 96-well Compact Jr crystallization plates from
Emerald BioSystems. Crystals were found under several PEG con-
ditions, while crystals suitable for X-ray diffraction experiments were
obtained from PACT condition H6: 20% PEG 3350, 200 mM sodium
formate, 100 mM Bis-Tris propane. The crystals were cryoprotected
by soaking them in a buffer consisting of 25% ethylene glycol mixed
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Table 1
Data-collection statistics.
Values in parentheses are for the highest resolution shell.
Beamline ALS 5.0.1
Wavelength (A ˚ ) 0.9774
Space group C2
Unit-cell parameters (A ˚ ,  ) a = 196.77, b = 66.09, c = 56.29,
  = 92.26
Resolution range (A ˚ ) 50–1.75 (1.80–1.75)
Mean I/ (I) 17.0 (2.5)
Rmerge† 0.073 (0.558)
Completeness (%) 99.9 (99.8)
Multiplicity 4.6 (4.1)
No. of unique reﬂections 72824 (5374)
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ.with reservoir solution. The crystals were vitriﬁed by plunging them
directly into liquid nitrogen.
2.3. Data collection and structural determination
Diffraction data were collected on the Berkeley Center for
Structural Biology ALS 5.0.1 beamline as part of the Collaborative
Crystallography program. The beamline uses a wavelength of
0.9774 A ˚ and is equipped with an ADSC Quantum 210 CCD
detector. The data were reduced in the monoclinic space group C2t o
1.75 A ˚ resolution with XDS/XSCALE (Kabsch, 1988, 2010; see
Table 1).
Packing density (Matthews, 1968) suggested the presence of
two molecules of aldose reductase in the asymmetric unit
(VM =1 . 5 8A ˚ 3 Da
 1, 52% solvent). A search of the PDB for sequence
homologyyieldeda humanaldose-reductase-likeprotein(AKR1B10)
as the closest homolog with known structure (PDB entry 1zua;
Gallego et al., 2007), with 43% sequence identity. A search model was
generated from molecule A of PDB entry 1zua using the CCP4
program CHAINSAW (Stein, 2008; Winn et al., 2011). The structure
was solved by molecular replacement with the CCP4 program Phaser
(McCoy et al., 2007); two molecules could be placed with high Z
scores. The model was then iteratively extended manually using Coot
(Emsley & Cowtan, 2004) followed by cycles of reciprocal-space
reﬁnement with the CCP4 program REFMAC5 (Murshudov et al.,
2011). The ﬁnal model was validated with the validation tools within
Coot and with MolProbity (Chen et al., 2010).
The ﬁnal model was reﬁned at 1.75 A ˚ resolution to Rwork = 0.144
and Rfree = 0.173 with good stereochemistry (see Table 2). The
observed structure extends from residue Ser0 (part of the puriﬁcation
tag) to Asp313 in both chains. The loop between residues Ala111 and
Thr119 could not be modeled owing to weak electron density. One
NADP
+ molecule and one ethylene glycol molecule were modelled in
each chain. The nicotinamide ring of the cofactor is planar; hence, we
assume that NADP
+ is bound to the protein in the oxidized form.
The identity of a slightly prolate spheroid of electron density close to
the nicotinamide ring of NADP
+ could not be established and was
therefore modelled as ‘unknown atoms’ (UNK). A total of 611 water
molecules were located.
3. Results and discussion
G. lamblia aldose reductase adopts a TIM-barrel fold with the
NADP
+-binding site located within the eight  -strands of the interior
structural communications
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Table 2
Reﬁnement and model statistics.
Beamline ALS 5.0.1
Resolution range (A ˚ ) 50–1.75
Rcryst† 0.144
Rfree† 0.173
R.m.s.d. bonds (A ˚ ) 0.016
R.m.s.d. angles ( ) 1.56
Protein atoms 4908
Nonprotein atoms 767
Mean B factor (A ˚ 2) 16.7
Residues in favoured region 580 (97.2%)
Residues in allowed region 17 (2.9%)
Residues in disallowed region 0 (0%)
MolProbity‡ score (percentile) 1.13 (99th)
PDB code 3krb
† Rcryst =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj. The free R factor was calculated using 5% of
the reﬂections omitted from the reﬁnement (Winn et al., 2011). ‡ Chen et al. (2010).
Figure 1
Dimer of aldose reductase from G. lamblia (GilaA.01452.aA1). Aldose reductase
from G. lamblia forms a dimer of two TIM barrels. In this ﬁgure the twofold axis
runs approximately vertically. The helices of the two monomers are shown as blue
and purple ribbons. In each momomer, an NADP molecule is visible at the
C-terminal end of the strands of the  -barrel. This ﬁgure was prepared with
CCP4mg (McNicholas et al., 2011).
Figure 2
(a) NADP is well deﬁned in the structure of G. lamblia aldose reductase. (b)T h e
adenine ring of NADP stacks hydrophobically with the side chains of His242 and
Arg269. While Arg269 is conserved between human and Giardia aldose reductase,
His242 of Giardia aldose reductase is an alanine in the human enzyme. This ﬁgure
was prepared with CCP4mg (McNicholas et al., 2011). In both cases  A-weighted
2|Fo|   |Fc| electron density is shown in blue at 1  and  A-weighted |Fo|   |Fc|
electron density is shown in green and red at  3 .(Fig. 1). Sequence alignment with Homo sapiens aldose reductase
shows 44% identity; no structures in the PDB have an identity greater
than 50%. The two monomers of G. lamblia aldose reductase super-
impose with a root-mean-square deviation (r.m.s.d.) of 0.3 A ˚ (on C
 
atoms); a search of the PDB for structural homologues using SSM/
PDBeFold (Krissinel & Henrick, 2004) yielded several structures
of human aldose reductase with C
 -atom r.m.s.d.s of 1.0–1.1 A ˚ . When
compared with the structure of mammalian aldose reductase, subtle
variations in structure are apparent.
There is a distinct structural divergence of the N-termini of
G. lamblia aldose reductase and the human protein: while the
N-terminal 14 residues of both structures are well ordered, G. lamblia
aldose reductase lacks the small N-terminal capping  -sheet exhib-
ited by mammalian structures (residues 2–14 of human aldose
reductase).
Cofactor binding by Arg269 is conserved between the two struc-
tures. The side chain of His242 of G. lamblia aldose reductase
hydrophobically stacks with the adenine of NADP
+, while this
residue is an alanine in the human protein (Fig. 2). This histidine
residue is not found in other aldose reductases of higher organisms
and may be unique to Giardia. A ﬂexible loop between the strand
and helix 7 of the  / -barrel (dubbed the ‘safety belt’) has previously
been reported to sequester solvent from the NADP
+ cofactor (Wilson
et al., 1992). This ﬂexible feature was not resolved in this structure.
Tantalizingly, this region shows divergence between the mammalian
and Giardia sequences. Sequence comparison with human aldose
reductase by ClustalW (Larkin et al., 2007) analysis (Fig. 3) indicates
that phenylalanine residues at positions 109 and 118 are conserved
participants in forming the hydrophobic substrate-speciﬁcity pocket.
Other residues identiﬁed as components of the mammalian speciﬁcity
pocket (Klebe et al., 2004; Harrison et al., 1994; Sotriffer et al., 2004;
Urzhumtsev et al., 1997) are divergent (Table 3). The residues of the
anion-binding pocket and the active site appear to be completely
conserved (Table 3) and their orientation is conserved in the three-
dimensional structure. The residues ﬂanking the C-terminal mobile
region appear to be conservative substitutions, while the interior
residues of this short region show no conservation (Table 3).
The structure of the G. lamblia aldose reductase was superimposed
with ligand-bound aldose reductases such as human aldose reductase
in complex with ﬁdarestat (PDB entry 1ef3; Oka et al., 2010) and
porcine aldose reductase in complex with tolrestat (PDB entry 1ah3;
Urzhumtsev et al., 1997) or sorbinil (PDB entry 1ah0; Urzhumtsev et
al., 1997). All three inhibitors bind in close proximity to the
nicotinamide group of NADP (Fig. 4). The protein models super-
impose well overall, with r.m.s.d.s of 1.06 A ˚ (1ef3), 1.03 A ˚ (1ah3) and
1.13 A ˚ (1ah0). Despite high overall structural homology, there is a
distinct difference in structure, separate from the mobile regions
deﬁned earlier, between the G. lamblia and mammalian enzymes
close to the inhibitor-binding site. The C-terminal loop formed by
residues Pro303–Leu311 diverges signiﬁcantly from the structure of
the corresponding loop in the human and porcine structures. In the
human and porcine structures this loop is much more conserved and
interacts with the inhibitors. In addition, structural rearrangements
would be necessary for G. lamblia aldose reductase to harbor any of
these three inhibitors. This structural diversity of the ligand-binding
pocket in turn provides opportunities for the design of drugs that are
speciﬁc for G. lamblia aldose reductase.
4. Conclusion
The structure of G. lamblia aldose reductase in complex with NADP
+
was solved to a resolution of 1.75 A ˚ . Residues in the active site and
anion-binding pocket show conservation in sequence and structure
with mammalian structures, while the nonphenylalanine residues
involved in forming the speciﬁcity pocket show divergence. This
structure did not resolve a ﬂexible loop involved in solvent
structural communications
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Figure 3
ClustalW (Larkin et al., 2007) comparison of the amino-acid sequences of H. sapiens and G. lamblia aldose reductase.
Table 3
Conservation of residues involved in substrate binding.
H. sapiens G. lamblia
Speciﬁcity pocket Thr114 Leu107
Cys304 Ala304
Tyr310 Pro310
Anion-binding pocket Trp21 Trp12
Val48 Val39
Tyr49 Tyr40
His111 His104
Trp112 Trp105
Lys78 Lys71
Asp44 Asp35
C-terminal mobile region Val298 Ile297
Cys304 Ala304
Ala299 Phe299
Leu300 Cys301sequestration of NADP
+. A conserved arginine residue is involved in
cofactor binding together with an apparently Giardia-speciﬁc histi-
dine residue.
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Figure 4
Inhibitor-binding pocket of G. lamblia aldose reductase in comparison with ligand-
bound human and porcine aldose reductases. G. lamblia aldose reductase (red
model) superimposes with small r.m.s.d.s with human aldose reductase in complex
with ﬁdarestat (PDB entry 1ef3, dark blue) and porcine aldose reductase in
complex with tolrestat (PDB entry 1ah3, green) and sorbinil (PDB entry 1ah0,
cyan). Despite the overall structural homology, the C-terminal loop, which interacts
with the ligand, shows a distinctly different trace. For clarity, the C atoms of the
inhibitors follow the same color scheme as the corresponding ribbon. The NADP
molecule is shown only for G. lamblia, with light green C atoms. This ﬁgure was
prepared with CCP4mg (McNicholas et al., 2011).